Humana Valuation

Is HUM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HUM (SEK26.3) is trading below our estimate of fair value (SEK92.66)

Significantly Below Fair Value: HUM is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HUM?

Other financial metrics that can be useful for relative valuation.

HUM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA13.2x
PEG Ratio0.4x

Price to Earnings Ratio vs Peers

How does HUM's PE Ratio compare to its peers?

The above table shows the PE ratio for HUM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.1x
AMBEA Ambea
12.4x15.4%kr5.6b
ATT Attendo
19.9x22.6%kr7.5b
EQL EQL Pharma
55.4x81.2%kr1.2b
DEDI Dedicare
8.7x1.7%kr958.2m
HUM Humana
7.1x18.2%kr1.3b

Price-To-Earnings vs Peers: HUM is good value based on its Price-To-Earnings Ratio (7.1x) compared to the peer average (24.1x).


Price to Earnings Ratio vs Industry

How does HUM's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a33.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a33.0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: HUM is good value based on its Price-To-Earnings Ratio (7.1x) compared to the European Healthcare industry average (18.6x).


Price to Earnings Ratio vs Fair Ratio

What is HUM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HUM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.1x
Fair PE Ratio31.1x

Price-To-Earnings vs Fair Ratio: HUM is good value based on its Price-To-Earnings Ratio (7.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HUM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr26.30
kr33.50
+27.4%
19.4%kr40.00kr27.00n/a2
Apr ’25kr24.55
kr33.50
+36.5%
19.4%kr40.00kr27.00n/a2
Mar ’25kr25.30
kr33.50
+32.4%
19.4%kr40.00kr27.00n/a2
Feb ’25kr25.85
kr34.50
+33.5%
15.9%kr40.00kr29.00n/a2
Jan ’25kr28.15
kr37.00
+31.4%
21.6%kr45.00kr29.00n/a2
Dec ’24kr27.65
kr37.00
+33.8%
21.6%kr45.00kr29.00n/a2
Nov ’24kr26.70
kr34.50
+29.2%
15.9%kr40.00kr29.00n/a2
Oct ’24kr26.60
kr34.50
+29.7%
15.9%kr40.00kr29.00n/a2
Sep ’24kr29.60
kr34.50
+16.6%
15.9%kr40.00kr29.00n/a2
Aug ’24kr28.00
kr34.50
+23.2%
15.9%kr40.00kr29.00n/a2
Jul ’24kr22.20
kr17.00
-23.4%
14.4%kr20.00kr14.00n/a3
Jun ’24kr15.04
kr17.00
+13.0%
14.4%kr20.00kr14.00n/a3
May ’24kr14.46
kr16.67
+15.3%
17.2%kr20.00kr13.00n/a3
Apr ’24kr14.76
kr17.33
+17.4%
11.9%kr20.00kr15.00kr24.553
Mar ’24kr14.34
kr17.33
+20.9%
11.9%kr20.00kr15.00kr25.303
Feb ’24kr21.35
kr45.67
+113.9%
47.9%kr70.00kr17.00kr25.853
Jan ’24kr38.50
kr64.33
+67.1%
6.3%kr70.00kr61.00kr28.153
Dec ’23kr42.95
kr64.33
+49.8%
6.3%kr70.00kr61.00kr27.653
Nov ’23kr42.25
kr71.67
+69.6%
8.7%kr80.00kr65.00kr26.703
Oct ’23kr48.50
kr71.67
+47.8%
8.7%kr80.00kr65.00kr26.603
Sep ’23kr43.15
kr71.67
+66.1%
8.7%kr80.00kr65.00kr29.603
Aug ’23kr48.45
kr74.33
+53.4%
5.6%kr80.00kr70.00kr28.003
Jul ’23kr44.80
kr76.00
+69.6%
3.9%kr80.00kr73.00kr22.203
Jun ’23kr49.35
kr76.50
+55.0%
4.6%kr80.00kr73.00kr15.042
May ’23kr51.80
kr81.50
+57.3%
4.3%kr85.00kr78.00kr14.462
Apr ’23kr58.80
kr86.50
+47.1%
9.8%kr95.00kr78.00kr14.762

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.